Charles River Laboratories (CRL) Q1 2025 10-Q Quarterly Report
Filed: May 7, 2025Period ending Mar 29, 2025
Industrials
Services-Commercial Physical & Biological ResearchSEC EDGAR Charles River Laboratories (CRL) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 7, 2025 for the fiscal period ending Mar 29, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Charles River Laboratories Q1 2025 10-Q Analysis
Risk Factors
- • New risk from U.S. tariffs on imports from Vietnam, Mauritius, and China impacting supply chain and operating margin as of early April 2025
- • Most updated risk: NIH policy reducing research grants for indirect overhead announced Feb 7, 2025, currently under preliminary injunction but with uncertain final outcome
- • Regulatory risk: FDA 2025 plan to reduce animal testing in preclinical studies may materially affect demand for animal-based research services
- • Operational risk: Potential demand reduction if drug approval processes are streamlined or regulatory requirements become less stringent globally
- • Financial risk: Revenue exposure to government R&D funding volatility, especially NIH, affecting timing and level of client purchases in the RMS segment
Charles River Laboratories Q1 2025 Quarterly FinancialsXBRL
Revenue
$984M
▼ -2.7% YoY
Net Income
$25M
▼ -65.1% YoY
Net Margin
2.6%
▼ -462bp YoY
Source: XBRL data from Charles River Laboratories Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Charles River Laboratories Quarterly Reports
Get deeper insights on Charles River Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.